Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
Saved in:
| Title: | Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). |
|---|---|
| Authors: | Girolomoni, Giampiero1 (AUTHOR), Feldman, Steven R.2 (AUTHOR), Egeberg, Alexander3,4 (AUTHOR), Puig, Luis5 (AUTHOR), Jung, Jinah6 (AUTHOR), Jung, Hojung6 (AUTHOR), Lee, Younju6 (AUTHOR) |
| Source: | Journal of Dermatological Treatment. Dec2024, Vol. 35 Issue 1, p1-7. 7p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 09546634 |
|---|---|
| DOI: | 10.1080/09546634.2024.2434091 |
